Publication:
Adenosine deaminase, not immune to a mechanistic rethink in central nervous system disorders?

Thumbnail Image
Files
Hall-37-189-212-2022.pdf(4.37 MB)
Date
2022
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Hall, Benjamin ; George, Jonathan G. ; Allen, Scott P.
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia, Departamento de Biologia Celular e Histiologia
publication.page.editor
publication.page.department
DOI
https://doi.org/ 10.14670/HH-18-404
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Adenosine deaminase (ADA) is a purine metabolism enzyme that catalyses the breakdown of adenosine and deoxyadenosine. The enzyme is important in several cellular processes, including the innate immune response and cellular differentiation, and it is also an important enzyme for the maintenance of brain homeostasis, in part due to its regulation of adenosine. Aberrant regulation of ADA enzyme activity has been linked to several neurodegenerative diseases and diseases that can result in neurological impairment. However, the mechanisms behind altered ADA regulation and how this leads to the development of neurological dysfunction are poorly characterised. This review summarises the current research on ADA and its role and regulation in disease pathology, with a focus on the central nervous system (CNS) and the neurodegenerative disease, amyotrophic lateral sclerosis (ALS)
publication.page.subject
Adenosine deaminase , Central nervous system , Pathology , Severe combined immunodeficiency , Amyotrophic lateral sclerosis
Citation
Histology and Histopathology Vol. 37, nº3 (2022)
URI
http://hdl.handle.net/10201/128325
item.page.embargo
Collections
Histology and histopathology Vol.37, nº3 (2022)
Ir a Estadísticas